Piplartine showed antiproliferative activity against other cancer cells without affecting normal cells in vitro and in vivo [150,151,152], and it was discovered that it modulates cell signaling pathways that play crucial roles in the initiation and progression of cancer, such as the PI3K/Akt/mTOR, NF-κB, JAK/STAT3 and ERK signaling pathways [153]. This evidence concerns the gene STAT3 and cancer.